Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Opinion and Comment
Nature Biotechnology 27, 419–420 (1 May 2009) | doi:10.1038/nbt0509-419b
Regulating laboratory-developed tests
&
Abstract
To the Editor: You argue in your March editorial that the US Food and Drug Administration (FDA; Rockville, Maryland) should keep out of the regulation of genetic tests. The editorial is framed as a reaction to a petition Genentech (South San Francisco, California, USA) filed with FDA last December proposing that the agency regulate genetic tests on the basis of their complexity and risk, not on whether they're produced in-house (with little or no oversight) or as a commercial kit (which means they will have gone through all the available regulatory hoops to ensure public safety).
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
